Boehringer Ingelheim Debuts First Approved Therapy for Equine Insulin Dysregulation in UK — Boehringer Ingelheim International GmbH

Event summary

Boehringer Ingelheim launched SCOVELLA®, the first approved therapy for hyperinsulinemia in insulin-dysregulated horses and ponies, in Great Britain on September 1, 2026.
SCOVELLA® (velagliflozin oral solution) is an equine-specific SGLT-2 inhibitor that reduces hyperinsulinemia, a key driver of laminitis, within days of treatment.
Insulin dysregulation affects an estimated one in five horses and is the primary cause of laminitis, with one-third of affected horses euthanized within a year of diagnosis.
The therapy will be available to prescribing veterinary surgeons in Great Britain, with plans to expand to other markets in the future.

The big picture

Boehringer Ingelheim's launch of SCOVELLA® addresses a significant unmet need in equine health, targeting the primary cause of laminitis, a condition with high morbidity and mortality rates. The introduction of the first licensed therapy for insulin dysregulation in horses underscores the company's commitment to innovation in animal health. This strategic move positions Boehringer Ingelheim as a leader in equine medicine, potentially expanding its market presence and reinforcing its role in advancing veterinary care.

What we're watching

Market Expansion: The pace at which Boehringer Ingelheim can secure regulatory approvals and launch SCOVELLA® in other markets will determine the therapy's global reach and revenue potential.
Treatment Efficacy: Whether SCOVELLA® can sustain its rapid and significant reduction of hyperinsulinemia in real-world settings will be critical for long-term adoption by veterinarians and horse owners.
Competitive Dynamics: How existing and potential competitors respond to SCOVELLA®'s entry into the equine insulin dysregulation treatment space could influence market share and pricing strategies.